JP2014162726A - Functional compositions - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a highly safe functional composition, of which ingestion or administration in a small amount prevents or improves bone metabolism disorder, inhibits fat accumulation, improves dermal water retention, inhibits skin pigment deposition and promotes hyaluronic acid production.SOLUTION: Combination use of β-cryptoxanthin and resveratrol synergistically enhances activities such as prevention or improvement of bone metabolism disorder, anti-obesity, improvement of water retention of skin, inhibition of pigment deposition in skin, improvement of wrinkle, and enhancement of hyaluronic acid production.

Description

  The present invention relates to a functional composition effective for preventing or improving abnormal bone metabolism, suppressing fat accumulation, improving skin water retention, suppressing skin pigmentation, promoting hyaluronic acid production, and the like. Moreover, this invention relates to the food / beverage products, food additive, cosmetics, pharmaceuticals, feed, and pet food using the said functional composition.

  Aging is known to cause hormonal balance changes. For example, dehydroepiandrosterone is a sex hormone involved in the synthesis of hormones such as testosterone and corticosterone. In the 60s, only 10-20% of the 20s has dehydroepiandrosterone secretion. It is known that it will not. Similarly, estradiol, which is also a sex hormone, is known to rapidly decrease in 3 to 4 years from the last menstruation (Non-patent Document 1). It is known that these changes in hormonal balance associated with aging cause a decrease in biological function. For example, it is known that the aforementioned testosterone increases energy consumption in muscles, and it is known that the amount of testosterone and obesity are inversely correlated (non-patent document 2). In the skin, it is known that a decrease in estrogen, which is a type of sex hormone, affects the division of skin cells and hyaluronic acid synthesis, and estrogen supplementation alleviates these symptoms (Non-patent Document 3). ). Thus, aging contributes to various symptoms such as abnormal bone metabolism, obesity, dry skin, spots, freckles, and wrinkles through various factors.

  In Japan, the aging population is declining and the working population is decreasing. On the other hand, the burden on each worker continues to increase due to the economic downturn. It is a universal desire to be youthful forever, but in today's stressed society it is not easy to meet this desire. In addition, the declining birthrate and aging population have put pressure on the government's finances due to soaring medical expenses and a decrease in tax revenues. In order to improve the above points, it is desirable to improve various symptoms such as aging.

  In addition to aging, the above-mentioned symptoms are known to be caused by photoaging due to exposure to stress, ultraviolet rays, etc., lifestyle disturbances due to excessive nutrition, lack of exercise, etc., which is a major problem. ing.

  Conventionally, various investigations have been made on components and compositions that prevent or ameliorate the aforementioned symptoms. For example, Patent Document 1 reports that specific animal and plant sterols containing 24-methylenecholesterol can exhibit an excellent estrogen-like action and are effective in preventing osteoporosis. Patent Document 2 reports that a fish bone paste obtained by subjecting a fish bone to pressure and heat treatment, followed by collagen degradation and refinement is effective in preventing or treating osteoporosis. Patent Document 3 reports that the extract from Tochu leaf water obtained through a predetermined treatment has an anti-obesity effect. Patent Document 4 reports that a candy containing a collagen hydrolyzate and / or mucopolysaccharide and a natural antioxidant has high antioxidant properties and can suppress excessive accumulation of melanin. Patent Document 5 discloses that at least one selected from an extract of fermented moon peach, an extract of fermented mugwort, an extract of fermented guava, an extract of fermented Japanese algae, and an extract of fermented turmeric It has been reported that it has obesity action and hyaluronidase activity inhibition action. However, each of the techniques of Patent Documents 1 to 5 has a problem in that the effects are not sufficient by itself, and the amount of blending cannot be increased from the viewpoint of blending design problems and side effects.

  With such a conventional technology as a background, functionally effective in preventing or improving bone metabolism abnormalities, suppressing fat accumulation, improving skin water retention, suppressing skin pigmentation, promoting hyaluronic acid production, etc. safely with a small amount of ingestion or administration Development of compositions is desired.

JP 2005-139150 A International Publication No. 2007/066664 JP 2007-238449 A Japanese Patent Laid-Open No. 9-9872 JP 2009-242261 A

Hormonal Changes in the Menopause Transition, Henry G et al. Recent Prog Horm Res. 2002; 57: 257-75 Androgen receptor-deficient mice and obesity, Toshihiko Yanase et al. Obesity Research, 2006, Vol. 12, pp. 172-5 Skin aging and sex hormones in women-clinical perspectives for intervention by hormone replacement therapy.Sator P-G et al. Experimental Dermatology 2004 suppl. 4 36-40.

  The present invention is a functional composition that is highly safe and effective in preventing or improving bone metabolism abnormalities, suppressing fat accumulation, improving skin water retention, suppressing skin pigmentation, promoting hyaluronic acid production, etc. by ingestion or administration in small amounts. The purpose is to provide. Moreover, this invention aims at providing the food-drinks, food additive, cosmetics, pharmaceuticals, pet food, and feed using the said functional composition.

  As a result of intensive studies to solve such problems, the present inventors have used or combined β-cryptoxanthin and resveratrol to prevent or improve abnormal bone metabolism, anti-obesity, and skin water retention. It has been found that effects such as improvement, suppression of skin pigmentation, improvement of wrinkles, and promotion of hyaluronic acid production are synergistically enhanced. The present invention has been completed by further studies based on such knowledge.

That is, this invention provides the invention of the aspect hung up below.
Item 1. At least one β-cryptoxanthin selected from the group consisting of β-cryptoxanthin and derivatives thereof, and at least one resveratrol selected from the group consisting of resveratrol, derivatives thereof, and salts thereof The functional composition characterized by including the kind.
Item 2. Item 2. The functional composition according to Item 1, wherein the β-cryptoxanthin is derived from citrus fruits.
Item 3. Item 3. The functional composition according to Item 1 or 2, wherein the resveratrol is derived from salmon.
Item 4. Item 2. The functional composition according to Item 1, which is used as an agent for preventing or improving bone metabolism abnormality, a fat accumulation inhibitor, a skin water retention agent, a skin pigmentation inhibitor, and / or a hyaluronic acid production promoter.
Item 5. Any one of Items 1 to 4, which is used as an agent for preventing or improving osteoporosis, an anti-obesity agent, an agent for preventing or improving metabolic syndrome, a moisturizer, a whitening agent, a skin beautifying agent, and / or a wrinkle preventing or improving agent. The functional composition described.
Item 6. Item 6. The functional composition according to any one of Items 1 to 5, which is applied by oral ingestion or transdermal administration.
Item 7. Food / beverage products which have the functional composition in any one of claim | item 1 -6.
Item 8. Item 8. The food and drink according to Item 7, which is used for at least one application selected from the group consisting of prevention or improvement of abnormal bone metabolism, suppression of fat accumulation, improvement of skin water retention, suppression of skin pigmentation, and promotion of hyaluronic acid production. Goods.
Item 9. Item 7 or 8 used in at least one application selected from the group consisting of prevention or improvement of osteoporosis, prevention or improvement of anti-obesity, metabolic syndrome, moisturizing, whitening, skin beautification, and prevention or improvement of wrinkles. The listed food and drink.
Item 10. Item 10. The food or drink according to any one of Items 7 to 9, which is used for anti-aging.
Item 11. The food additive which has a functional composition in any one of claim | item 1 -6.
Item 12. Item 12. The food according to Item 11, which is used for at least one application selected from the group consisting of prevention or improvement of abnormal bone metabolism, suppression of fat accumulation, improvement of skin water retention, suppression of skin pigmentation, and promotion of hyaluronic acid production. Additive.
Item 13. Item 11 or 12 is used for at least one application selected from the group consisting of prevention or improvement of osteoporosis, anti-obesity, prevention or improvement of metabolic syndrome, moisturizing, whitening, skin beautification, and prevention or improvement of wrinkles. The food additive described.
Item 14. Item 14. The food additive according to any one of Items 11 to 13, which is used for anti-aging.
Item 15. Cosmetics which have a functional composition in any one of claim | item 1 -6.
Item 16. Item 16. The cosmetic according to Item 15, which is used for at least one application selected from the group consisting of improving skin water retention, suppressing skin pigmentation, and promoting hyaluronic acid production.
Item 17. Item 17. The cosmetic according to Item 15 or 16, which is used for at least one application selected from the group consisting of moisturizing, whitening, skin beautification, and prevention or improvement of wrinkles.
Item 18. Item 18. The cosmetic according to any one of Items 15 to 17, which is used for skin aging prevention.
Item 19. Item 7. A pharmaceutical product comprising the functional composition according to any one of Items 1 to 6.
Item 20. Item 20. The pharmaceutical product according to Item 19, which is used for at least one application selected from the group consisting of prevention or improvement of abnormal bone metabolism, suppression of fat accumulation, improvement of skin water retention, suppression of skin pigmentation, and promotion of hyaluronic acid production. .
Item 21. Item 19 or 20 used in at least one application selected from the group consisting of prevention or improvement of osteoporosis, anti-obesity, prevention or improvement of metabolic syndrome, moisturizing, whitening, skin beautification, and prevention or improvement of wrinkles The listed medicine.
Item 22. Item 22. The medicine according to any one of Items 19 to 21, which is used for anti-aging.
Item 23. Claim | item 1-6 feed or pet food which has a functional composition in any one.
Item 24. Item 24. The feed according to Item 23, which is used for at least one application selected from the group consisting of prevention or improvement of abnormal bone metabolism, suppression of fat accumulation, improvement of skin water retention, suppression of skin pigmentation, and promotion of hyaluronic acid production. Or pet food.
Item 25. Item 23 or 24 is used for at least one application selected from the group consisting of prevention or improvement of osteoporosis, prevention or improvement of anti-obesity, metabolic syndrome, moisturizing, whitening, skin beautification, and prevention or improvement of wrinkles. Feed or pet food as described.
Item 26. Item 26. The feed or pet food according to any one of Items 23 to 25, which is used for anti-aging.

  Since the functional composition of the present invention can prevent or improve abnormal bone metabolism, it is useful for preventing or improving osteoporosis and the like. In addition, since the functional composition of the present invention can suppress fat accumulation, it is effective in reducing visceral fat and anti-obesity such as dieting, and is also effective in preventing or improving metabolic syndrome. Furthermore, since the functional composition of the present invention also exhibits effects such as improvement of skin water retention, suppression of skin pigmentation, and promotion of hyaluronic acid production, moisturizing, whitening (reducing spots and freckles, etc.), beautiful skin, wrinkle It is also effective for prevention or improvement. As described above, the functional composition of the present invention is effective as an anti-aging agent because it can prevent or ameliorate symptoms caused by a decrease in biological function caused by aging.

  In addition, the functional composition of the present invention is effective in preventing or improving abnormal bone metabolism, suppressing fat accumulation, improving skin water retention, suppressing skin pigmentation, promoting hyaluronic acid production, etc. Therefore, even if it is ingested or administered in a small amount, the desired effect can be enjoyed effectively. Furthermore, since the functional composition of this invention uses the component contained in the natural raw material with food experience, it has high safety | security.

In Experiment 1, it is a figure which shows the result of having evaluated the effect | action which the functional composition of this invention has on bone metabolism. In Experiment 2, it is a figure which shows the result of having evaluated the effect | action which the functional composition of this invention has on fat accumulation. In Experiment 3, it is a figure which shows the result of having evaluated the effect | action which the functional composition of this invention has on melanin production. In Experiment 4, it is a figure which shows the result of having evaluated the effect | action which the functional composition of this invention has on the transdermal moisture transpiration | evaporation amount of skin. In Experiment 4, it is a figure which shows the result of having evaluated the effect | action which the functional composition of this invention has on a wrinkle. In Experiment 5, it is a figure which shows the result of having evaluated the effect | action which the functional composition of this invention has on hyaluronic acid production.

  The functional composition of the present invention is selected from the group consisting of at least one β-cryptoxanthin selected from the group consisting of β-cryptoxanthin and derivatives thereof, and resveratrol, derivatives thereof, and salts thereof. Characterized in that it contains at least one resveratrol. Hereinafter, the functional composition of the present invention will be described.

β-Cryptoxanthin In the functional composition of the present invention, the β-cryptoxanthin contains at least one selected from the group consisting of β-cryptoxanthin and its derivatives.

  About (beta) -cryptoxanthin, about the isomer type, it does not restrict | limit in particular, Either all-trans type | mold or cis type may be sufficient.

  Although it does not restrict | limit especially as a derivative | guide_body of (beta) -cryptoxanthin, For example, a fatty acid ester body, a sulfate ester body, a hydroxyl group addition body, a dehydroxylation body, a glycoside etc. are mentioned. The type of the fatty acid ester of β-cryptoxanthin is not particularly limited as long as the fatty acid is ester-bonded to β-cryptoxanthin. Although it does not restrict | limit especially about the fatty acid which comprises the fatty acid ester body of (beta) -cryptoxanthin, For example, C8-C32, Preferably it is C10-24 saturated or unsaturated fatty acid is mentioned. Specific examples of the fatty acid include lauric acid (C12), myristic acid (C14), palmitic acid (C16), and stearic acid (C18). These fatty acid esters of cryptoxanthin are contained in Satsuma oranges, and those derived from Satsuma oranges are preferably used as the fatty acid esters of β-cryptoxanthin. In addition, the type of sugar component in the glycoside of β-cryptoxanthin is not particularly limited, and monosaccharides such as glucose, mannose and galactose; disaccharides such as sucrose, lactose and trehalose; Can be mentioned. Further, the type of isomer of these β-cryptoxanthin derivatives is not particularly limited, and may be either cis type or trans type. These derivatives of β-cryptoxanthin may be used singly or in combination of two or more.

  In the functional composition of the present invention, β-cryptoxanthins may be used by selecting one from β-cryptoxanthin and derivatives thereof, or may be used in combination of two or more. . Among the β-cryptoxanthins, β-cryptoxanthin is preferable.

  The origin of β-cryptoxanthin used in the present invention is not particularly limited, and may be a natural material (plant-derived or animal-derived) or extracted from a microorganism, and may be a chemical synthesis or an enzyme synthesis. It may be obtained by. From the viewpoints of safety, reduction in production cost, etc., it is preferable to use β-cryptoxanthins derived from natural materials.

  In the present invention, when β-cryptoxanthins derived from natural materials or microorganisms are used, the β-cryptoxanthins may be purified by removing other natural materials or components derived from microorganisms. Natural materials other than β-cryptoxanthins or components derived from microorganisms may be contained, and natural materials or extracts of microorganisms can be used as long as β-cryptoxanthins are contained.

  The animals and plants used as the raw material for β-cryptoxanthin are not particularly limited as long as β-cryptoxanthin is contained. Examples of animals and plants that contain β-cryptoxanthin include cereals such as brown rice and corn; sweet potatoes, sweet potatoes, sweet potatoes such as sweet potatoes, and processed products; azuki bean, sweet peas, peas, sweet potatoes, broad beans, daizu , Chickpeas, bean buns, beans, ramame, ryokuto, lentils, etc .; almonds, asa, sesame, cashew nuts, kaya, ginkgo, chestnut, walnut, coconut, sesame, shii, watermelon Seeds such as lotus, rhododendron, pistachio, sunflower, brazil nut, hazelnut, macadamia nut, pine, peanut, etc .; artichoke, morning glory, tomorrow, asparagus, udon, funniest, hill hijiki, okura, turnip, Pumpkin, mustard, cauliflower, kanpyo, chrysanthemum, cabbage, cucumber, gyojan , Kyosai, Mushrooms, Kinsai, Watercress, Kwai, Kale, Kohlrabi, Garbage, Burdock, Komatsuna, Zhasai, Santo Usagi, Shishigarashi, Shiso, Juicy Sasage, Spring Chrysanthemum, Junsai, Ginger, Shirou, Shizui , Sukikina, Zucchini, Seri, Celery, Mainspring, Taasai, Daikon, Daisai, Takana, Bamboo shoot, Onion, Tarame, Chicory, Chingensai, Japanese cypress, Tsunana, Tsurumura Saki, Tsubaki, Pepper, Tofu, Tomato Kind, trevis, tonbutsu, nagasaki haikui, eggplant, nazuna, nigari, leek, carrot, garlic, green onion, nozawana, stretch, Chinese cabbage, pakchoi, basil, parsley, hatsudaikon, Hayatouri, beet, peppers , Hinona, hiroshimana, wipes, everyday, broccoli, spinach Grass, Horseradish, Makomo, Mizukake, Trefoil, Myouga, Mukago, Mame, Sprouts, Morohaya, Yamagobo, Yuri, Yosai, Yamena, Yomogi, Rakikyo, Leek, Rhubarb, Lettuce, Lotus Vegetables such as agar, wasabi, bracken; acerola, avocado, apricot, strawberry, fig, yokan, plum, Wenzhou mandarin orange, olive, orange, oroblanco, salmon, pumpkin, karin, kiwifruit, kiwano, kumquat, guava, gooseberry , Gummy, grapefruit, gourd, cherry, sanbokan, shikuwasha, watermelon, sudachi, sumo, daidan, tongue, danzero, cherimoya, durian, summer mandarin, natsume, natsume palm, pineapple, lotus cup, hassaku, passion Fruit, banana, papaya, Fruits such as yuganatsu, loquat, blueberry, buntan, white support, ponkan, mokuwauri, quince, mango, melon, peach, yam, yuzu, raspberry, apple, lemon; , Arame, Iwanori, Enogori, Ogre Nori, Kawari, Constricted, Kelp, Suizenji Nori, Amakusa, Tosaka Nori, Hijiki, Higurashi, Funari, Matsumo, Mudori Nori, Mozukuri, Seaweed Seaweeds such as sea bream, sea bream, sea eel, eel, caviar, kochi, salmon and sardine sea bream, sea bream, sea bream, dojo, sea bream, sea bream, tuna, sea bream, and other fish; Shellfish such as oysters, oysters, sashimi, shijimi, tanishi, crush, fist, top shell, garlic, sea bream, clams, scallops, sea bream, potato Crustaceans such as shrimp and crab; cephalopods such as squid and octopus; seafood such as sea urchin, squirrel, jellyfish, shrimp, sea cucumber, sea bream; , Whales, deer, pigs, noodles, goats, Aigamo, poultry and other meats; eggs such as cocoon eggs, quail eggs, chicken eggs, and petan; milk and processed products such as milk. Among these animals and plants, citrus is preferable as a raw material for β-cryptoxanthin. Citrus species include plants belonging to the citrus family, and more specifically, Wenzhou mandarin oranges, Iyokan, summer mandarin oranges, oranges, kabosu, kawabata, kimizumikan, kiyomi, kumquat, grapefruit, gecko, sankan, shiikuwasa, bellows, Sweety, Sudachi, Daidai, Tachibana, Dekopon, Natsudaidai, Hassaku, Navel Orange, Valencia Orange, Hakuganatsu, Bungtan, Ponkan, Mandarin Orange, Yatsushiro, Yuzu, Lime, Lemon, Karatachi (Equivalent or similar varieties) Are also included). Among these citrus fruits, Unshu mandarin orange is particularly suitable as a raw material for β-cryptoxanthin because of its high production and high β-cryptoxanthin content.

  The microorganism used as a raw material for β-cryptoxanthin is not particularly limited as long as it has the ability to produce β-cryptoxanthin. Examples of microorganisms capable of producing β-cryptoxanthin include algae such as Dunaliella and Haematococcus; yeasts belonging to the genus Phaffia and Rhodotorula; genus Paracoccus and Sphingomonas. ), Bacteria belonging to the genus Brevundimonas, the genus Erythrobacter, and the like. Among these, from the viewpoint of the production ability of β-cryptoxanthins, preferably, bacteria belonging to the genus Paracoccus, Sphingomonas, Brevundimonas, and Erytlobacter. Specific examples of the bacterium belonging to the genus Paracoccus include Paracoccus carotinifaciens, Paracoccus marcusii, Paracoccus haeundaensis, Paracoccus haeundaensis (Paracoccus haeundaensis) ), Preferably Paracoccus carotinifaciens. Examples of specific bacterial strains belonging to the genus Paracoccus include Paracoccus carotinifaciens E-396 strain (FERM BP-4283), Paracoccus genus bacteria A-581-1 strain (FERM BP-4671), and these. Mutants of

  In order to extract β-cryptoxanthin from natural materials and / or microorganisms, pretreatment such as crushing, crushing, heating, dehydration, drying, etc. of natural materials and / or microorganisms containing β-cryptoxanthin is necessary. Is carried out by immersing in an extraction solvent while standing or stirring. The extraction solvent is not particularly limited as long as β-cryptoxanthin can be extracted. For example, alcohols such as methanol, ethanol, propanol, and butanol; ethylene glycol, propylene glycol, butylene glycol, glycerin, and the like Polyhydric alcohols; ketones such as acetone and methyl ethyl ketone; esters such as methyl acetate and ethyl acetate; ethers such as tetrahydrofuran and diethyl ether; halogenated hydrocarbons such as dichloromethane, dichloroethane and chloroform; hexane and pentane, etc. Aliphatic hydrocarbons; Aromatic hydrocarbons such as toluene; Polyethers such as polyethylene glycol; Organic solvents such as pyridines. These extraction solvents may be used alone or in combination of two or more. Among these extraction solvents, ethanol and hexane are particularly suitable when the functional composition of the present invention is used in the food field because it can ensure high safety. Moreover, in order to improve the extraction efficiency of (beta) -cryptoxanthin, you may add additives, such as water, an enzyme, and surfactant, in an extraction solvent as needed. The solvent extraction may be repeated a plurality of times.

  Moreover, extraction of (beta) -cryptoxanthin from a natural raw material and / or microorganisms can also be performed by supercritical extraction. The critical extraction is performed by bringing natural materials and / or microorganisms into contact with a supercritical fluid such as supercritical carbon dioxide after pretreatment such as crushing, crushing, heating, dehydration, and drying as necessary. be able to.

  The extract thus obtained is preferably subjected to a concentration treatment to obtain a concentrate in which the concentration of β-cryptoxanthin is increased. Examples of the concentration treatment include a method of removing the solvent by reducing pressure, heating, or the like. Furthermore, the concentrate may be subjected to a purification treatment to remove impurities as necessary. Examples of the purification treatment include column chromatography such as silica gel column chromatography, alkali treatment, desalting, activated carbon treatment, recrystallization method, partition purification, and the like. These purification processes may be performed by repeating the same process a plurality of times, or may be performed by combining two or more different processes. In addition, the obtained concentrate or product may be further subjected to processing such as pulverization or emulsification to adjust to a desired shape.

Resveratrol The functional composition of the present invention is at least one selected from the group consisting of resveratrol, derivatives thereof, and salts thereof as resveratrol in addition to the β-cryptoxanthin. Containing. Thus, by using β-cryptoxanthin and resveratrol together, the effects of bone metabolism abnormality prevention or improvement, fat accumulation suppression, skin water retention improvement, melanin production suppression, hyaluronic acid production promotion, etc. It can be improved and played.

  Resveratrol may be a monomer or a polymer in which two or more such as ε-viniferin and α-viniferin are polymerized. The double bond existing in resveratrol may be either trans or cis. These resveratrol may be used individually by 1 type, and may be used in combination of 2 or more type.

  The derivative of resveratrol is not particularly limited, and examples thereof include esters with fatty acids and glycosides. These resveratrol derivatives may be used alone or in combination of two or more.

  The salt of resveratrol and its derivatives is not particularly limited as long as it is edible, pharmaceutically acceptable, or cosmetically acceptable. For example, alkali such as lithium salt, sodium salt, potassium salt, etc. Metal salts; alkaline earth metal salts such as magnesium salts, calcium salts and barium salts; aluminum salts; metal hydroxide salts such as aluminum hydroxide salts; alkylamine salts, dialkylamine salts, trialkylamine salts, alkylenediamine salts, Amine salts such as cycloalkylamine salts, arylamine salts, aralkylamine salts, heterocyclic amine salts; amino acid salts such as α-amino acid salts, ω-amino acid salts; peptide salts or primary, first derived therefrom Secondary, tertiary or quaternary amine salts and the like can be mentioned. These salts may be used individually by 1 type, and may be used in combination of 2 or more type.

  The functional composition of the present invention may be selected from resveratrol, its derivatives, and salts thereof as resveratrols, or may be used in combination of two or more. May be. Among the resveratrols, resveratrol is preferable.

  The origin of resveratrol used in the present invention is not particularly limited and may be extracted from natural materials, or may be obtained by chemical synthesis or enzymatic synthesis. . From the viewpoint of safety, reduction in production cost, etc., it is preferable to use resveratrols derived from natural materials.

  In the present invention, when resveratrols derived from natural materials are used, the resveratrols may be purified by removing other natural materials or components derived from microorganisms. Natural materials or microorganism-derived components other than those may be contained, and natural materials or microorganism extracts can be used as long as resveratrol is included.

  The natural material used as a raw material for resveratrols is not particularly limited as long as resveratrols are included, and examples thereof include lepidopterous plants, teraceae plants (for example, itadori) and the like. It is done. Specific examples of legumes include Barbera, Cabernet Franc, Cabernet Sauvignon, Dolce, Dolhernder, Turtle, Grenache, Lenberger, Merlot, Mulvedor, Pinot Noir, Schiller, Malbec, Nebbiolo, and Pinotage , Primitivo, Refosco, Sangiovese, Tempranillo, Zinfandel, Arrigote, Chardonnay, Chasselas, Chenin Blanc, Fume Blanc, Frumint, Gewurztraminer, Gruener Feltner, Kellner, Morio Muscat, Muska, Muller Targau, Pinot Blanc, Pinot Gris, Riesling, Sauvignon Blanc, Schoelebe, Semen, Silvana, Trebbiano, Verdicchio, Vernacci , Koshu, Delaware, Muscat of Alexandria, Kyoho, Pione, Neo Muscat, Muscat Berry A, etc. Among these, the Cabernet Sauvignon, Merlot, Cabernet Franc, Pinot Noir, Chardonnay, Sauvignon Blanc, Semi-Yon, and Leasing, belonging to the European grape genus (Vitis Vinifera) and / or American grape (Vitis Labrusca) Has a high content of resveratrol and is preferable as a raw material natural material for resveratrol. When resveratrols are obtained from these vines, the raw material sites are not particularly limited as long as they contain resveratrols, and may be any of fruits, leaves, buds, and strawberries.

  In order to extract resveratrols from natural materials, pre-treatment such as crushing, crushing, heating, dehydration, drying, etc. is performed on the natural materials containing resveratrols, and then left in the extraction solvent. Or it is performed by immersing with stirring. The extraction solvent is not particularly limited as long as resveratrol can be extracted. For example, alcohols such as methanol, ethanol, propanol, and butanol; ethylene glycol, propylene glycol, butylene glycol, glycerin, etc. Polyhydric alcohols; Ketones such as acetone and methyl ethyl ketone; Esters such as methyl acetate and ethyl acetate; Ethers such as tetrahydrofuran and diethyl ether; Halogenated hydrocarbons such as dichloromethane, dichloroethane and chloroform; Fats such as hexane and pentane Aromatic hydrocarbons such as toluene; Polyethers such as polyethylene glycol; Organic solvents such as pyridines. These extraction solvents may be used alone or in combination of two or more. Among these extraction solvents, ethanol and hexane are particularly suitable when the functional composition of the present invention is used in the food field because it can ensure high safety. Moreover, in order to improve the extraction efficiency of resveratrol, you may add additives, such as water, an enzyme, and surfactant, in an extraction solvent as needed. The solvent extraction may be repeated a plurality of times.

  In addition, the extraction of resveratrols from natural materials can be performed by supercritical extraction. The critical extraction can be performed by bringing a natural material into contact with a supercritical fluid such as supercritical carbon dioxide after pretreatment such as crushing, crushing, heating, dehydration, and drying as necessary.

  The extract thus obtained is preferably subjected to a concentration treatment to obtain a concentrate with an increased concentration of resveratrol. Examples of the concentration treatment include a method of removing the solvent by reducing pressure, heating, or the like. Furthermore, the concentrate may be subjected to a purification treatment to remove impurities as necessary. Examples of the purification treatment include column chromatography such as silica gel column chromatography, alkali treatment, desalting, activated carbon treatment, recrystallization method, partition purification, and the like. These purification processes may be performed by repeating the same process a plurality of times, or may be performed by combining two or more different processes. In addition, the obtained concentrate or product may be further subjected to processing such as pulverization or emulsification to adjust to a desired shape.

Content and application amount of β-cryptoxanthin and resveratrol In the functional composition of the present invention, the ratio of β-cryptoxanthin and resveratrol is not particularly limited. The total amount of resveratrol is 0.1 to 300 parts by mass, preferably 1 to 300 parts by mass, and more preferably 10 to 250 parts by mass per 100 parts by mass of the xanthines.

  In the functional composition of the present invention, the content of β-cryptoxanthin and resveratrol is determined according to the type of product used, application, expected effect, application form, etc. Is set as appropriate as long as the above can be satisfied.

What is necessary is just to set suitably about the application amount of the functional composition of this invention according to the kind of product used, a use, the effect expected, an application form, etc. For example, in the case of oral application, the daily intake or dose of β-cryptoxanthin is 0.0001 to 100 g, preferably 0.001 to 10 g, more preferably 0.01 g to 1 g. It may be set so that the daily intake or dose of resveratrol for adults is 0.0001 to 100 g, preferably 0.001 to 10 g, more preferably 0.01 to 1 g. . Further, in a case that is applied transdermally, beta-applied weight 0.00001~1000μg / cm ² to 1 day skin cryptoxanthin acids, preferably 0.001~500μg / cm ^2, more preferably 0.01 to 100 / cm ² and set so that, the applied dose 0.0001~1000μg / cm ² to 1 day skin resveratrol compound, preferably 0.001~500μg / cm ^2, further What is necessary is just to set so that it may become 0.01-100 microgram / cm < ² > preferably.

Use of Functional Composition The functional composition of the present invention can be used in various applications by preparing β-cryptoxanthin and resveratrol as they are, or by adding an appropriate carrier as required to a desired form. used.

  For example, the functional composition of the present invention can be used as an agent for preventing or improving abnormal bone metabolism for the purpose of preventing or improving symptoms caused by abnormal bone metabolism such as osteoporosis.

  Further, the functional composition of the present invention can also be used as a fat accumulation inhibitor for the purpose of reducing visceral fat, anti-obesity such as diet, prevention or improvement of metabolic syndrome, and the like.

  Furthermore, the functional composition of the present invention can be used for the purpose of moisturizing as a skin water retention improver, and can prevent or improve skin symptoms caused by a decrease in skin water retention, such as dry skin, rough skin, and wrinkles. it can. In addition, the functional composition of the present invention can be used as a skin pigmentation inhibitor for the purpose of whitening, and can prevent or improve spots, freckles and the like. In addition, the functional composition of the present invention can also be used as a hyaluronic acid production promoter for the purpose of preventing or improving beautiful skin and wrinkles.

  In addition, since it is known that symptoms such as abnormal bone metabolism, fat accumulation, decreased skin water retention, skin pigmentation, and decreased hyaluronic acid production ability occur with aging, the functionality of the present invention The composition can also be used as an anti-aging agent.

Use Mode of Functional Composition Although the application form of the functional composition of the present invention is not particularly limited, for example, oral, transdermal, enteral, transmucosal, transvenous, arterial, subcutaneous, intramuscular, etc. Although it can be used in any application form, oral application or transdermal application is preferable from the viewpoint of achieving the above-described effects more effectively.

  The functional composition of the present invention can be used in various applications such as foods and drinks, cosmetics, pharmaceuticals, feeds, pet foods and the like because the functional composition of the present invention can be used in any application form and exhibit the desired effect.

  Moreover, the dosage form of the product in which the functional composition of the present invention is blended may be any of solid, semi-solid, liquid, and the like, and is appropriately set according to the type and application of the product. The product in which the functional composition of the present invention is blended includes water, fats and oils, waxes, hydrocarbons, fatty acids, and higher alcohols within the range that does not impair the effects of the present invention, depending on the form and the like. , Esters, plant extracts, water-soluble polymers, surfactants, metal soaps, alcohols, polyhydric alcohols, pH adjusters, antioxidants, UV absorbers, preservatives, fragrances, powders, thickening You may contain additives, such as an agent, a pigment | dye, and a chelating agent. Moreover, the product in which the functional composition of the present invention is blended may contain other functional components in a range not impairing the effects of the present invention, depending on the form, application, and the like. Examples of such functional components include vitamin C, collagen, squalane, niacin, niacinamide, hyaluronic acid, placenta extract, sorbitol, chitin, chitosan, various plant extracts, and the like. About these compounding quantities, unless the effect of this invention is impaired, it is not limited.

  When the functional composition of the present invention is used for food or drink, the β-cryptoxanthin and resveratrol are prepared as they are or in combination with other food materials and additive ingredients in the desired form. It is provided as a food or drink with effects. Examples of such foods and drinks include foods for specified health use, dietary supplements, functional foods, foods for the sick, and the like in addition to general foods and drinks. Although it does not restrict | limit especially as a form of these food / beverage products, Specifically, Main dishes, such as breads and noodles; Side dishes, such as cheese, ham, winner, and processed seafood; Fruit juice drink, carbonated drink, milk drink, etc. Beverages; cookies, cakes, jelly, pudding, candy, yogurt and other favorite products; tablets, granules, powders, capsules, soft capsules, nutritional drink supplements, etc. These foods and drinks can be used for the applications described above. In addition, the food for patients is provided for patients with diseases or symptoms caused by abnormal bone metabolism, fat accumulation, decreased skin water retention, skin pigmentation, decreased hyaluronic acid production ability, and the like.

  When using the functional composition of this invention for food-drinks, although the compounding quantity of this functional composition with respect to food-drinks differs according to the form etc. of food-drinks, (beta) -cryptoxanthin is 0. 0001 to 50 mass%, preferably 0.001 to 50 mass%, more preferably 0.01 to 50) mass%, and resveratrol is 0.0001 to 50 mass%, preferably 0.001 to 50 mass%. The range which becomes mass%, More preferably, it is 0.01-50 mass% is mentioned.

  Further, when the functional composition of the present invention is used in the field of foods and beverages, the functional composition of the present invention alone or in combination with other components is used as a food additive, preferably a food used for the above-mentioned use. It can also be provided as an additive. When the functional composition of the present invention is used as a food additive, the content of β-cryptoxanthin and resveratrol in the food additive, the amount of the food additive added to food and drink, etc. are added. It sets suitably so that (beta) -cryptoxanthin and resveratrol can satisfy the content mentioned above in the food / beverage products used as object.

  Further, when the functional composition of the present invention is used in cosmetics, the functional composition of the present invention is prepared in a desired form by combining with a cosmetically acceptable base material and additive components, It is provided as a cosmetic exhibiting a desired effect. The form of such cosmetics is not particularly limited, and specific examples include emulsions, creams, lotions, packs, cosmetic liquids, cleaning agents, makeup cosmetics, and the like. These cosmetics are used in the above-described applications, and are particularly preferably used in applications such as moisturizing, whitening, skin beautification, and anti-wrinkle. Moreover, the cosmetic containing the functional composition of the present invention can also be used as a cosmetic for preventing skin aging.

  When the functional composition of the present invention is used in a cosmetic, the blending ratio of the functional composition with respect to the cosmetic varies depending on the form of the cosmetic, for example, β-cryptoxanthin is 0. 000001-10 mass%, preferably 0.00001-10 mass%, more preferably 0.0001-10 mass%, and resveratrol is 0.000001-10 mass%, preferably 0.00001-10 mass%. %, More preferably a range of 0.0001 to 10% by mass.

  In addition, when the functional composition of the present invention is used for a pharmaceutical product, the functional composition of the present invention is desired alone or in combination with other pharmacologically active ingredients, pharmaceutically acceptable base materials and additive ingredients, etc. And is provided as a pharmaceutical product that exhibits the desired effect. Although it does not restrict | limit especially as a form of such a pharmaceutical, Specifically, oral administration formulation, such as a tablet, a granule, a powder agent, a capsule, a soft capsule, a syrup, external preparation, an inhalant, a suppository, etc. Transdermal or transmucosal preparations; injections and the like. These pharmaceuticals are used for the above-mentioned applications, but are preferably used for the prevention or improvement of abnormal bone metabolism and the suppression of fat accumulation, especially for the prevention or improvement of osteoporosis or the prevention or improvement of metabolic syndrome. Particularly preferably used.

  When the functional composition of the present invention is used as a pharmaceutical, the blending ratio of the functional composition with respect to the pharmaceutical varies depending on the form of the pharmaceutical, for example, β-cryptoxanthin is 0.0001 to 50 % By mass, preferably 0.001 to 50% by mass, more preferably 0.01 to 50% by mass, and resveratrol is 0.0001 to 50% by mass, preferably 0.001 to 50% by mass, Preferably the range used as 0.01-50 mass% is mentioned.

  Further, when the functional composition of the present invention is used for feed or pet food, the functional composition of the present invention is prepared in a desired form alone or in combination with other feed ingredients, and the desired effect is obtained. Provided as feed or pet food. Examples of feed ingredients used in the feed or pet food include cereals such as corn, wheat, barley and rye; brans such as bran and rice bran; moss such as corn gluten meal and corn jam meal; skim milk powder; Animal feeds such as whey, fish meal and bone meal; yeasts such as beer yeast; calciums such as calcium phosphate and calcium carbonate; vitamins; fats and oils; amino acids; The feed or pet food containing the functional composition of the present invention is used for the above-described applications, and is particularly preferably used for the prevention or improvement of abnormal bone metabolism and the suppression of fat accumulation. The feed or pet food containing the functional composition of the present invention can also be used for preventing aging of livestock, poultry, or pets.

  When the functional composition of the present invention is used as feed or pet food, the blending ratio of the functional composition to the feed or pet food varies depending on the form of the feed or pet food. Cryptoxanthines are 0.00001-10 mass%, preferably 0.0001-10 mass%, more preferably 0.001-10 mass%, and resveratrol is 0.00001-10 mass%, preferably The range which becomes 0.0001-10 mass%, More preferably, 0.01-10 mass% is mentioned.

  EXAMPLES The present invention will be specifically described below with reference to examples, but the present invention is not limited to these examples.

Test Example 1: Effect of β-cryptoxanthin and resveratrol on bone metabolism To examine the effects of β-cryptoxanthin and resveratrol on bone metabolism, osteoblast-like cell line MC3T3-E1 (RIKEN BioResource Center) Β-cryptoxanthin (trade name: β-cryptoxanthin manufactured by Shikoku Yasushi Pharmaceutical Co., Ltd.) and resveratrol (trade name: Resveratrol manufactured by Tokyo Chemical Industry Co., Ltd.) were administered to the product. The specific test method is as follows.

MC3T3-E1 cells are seeded in a 24-well plate (Asahi Techno Glass Co., Ltd.) so as to be 6.0 × 10 ⁴ cells, and once every two days, 10% FBS (fetal bovine serum; manufactured by Dainippon Sumitomo Pharma Co., Ltd.) ) And α-MEM (manufactured by Wako Pure Chemical Industries, Ltd.). After culturing for 3 days after seeding, cells that have reached sub-confluence are washed with PBS (Phosphate buffered saline), and a medium containing α-MEM and various components at the predetermined concentrations shown in Table 1 (without FBS) And cultured for 48 hours. After completion of the culture, the medium was removed from the wells, the cells were washed with PBS, and RNA was extracted with an RNA extraction reagent Isogen (manufactured by Nippon Gene Co., Ltd.) according to a conventional method. Thereafter, RNA is reacted with reverse transcriptase (manufactured by Takara Bio Inc.), using primers (manufactured by Sigma-Aldrich) that detect each marker gene of Runx2 type I, α1 (I) collagen, and Alkaline phosphatase, The expression level of each of these marker genes was measured. The expression level of each marker gene is a relative value obtained by calculating the ratio of the expression level of the GAPDH (glyceraldehyde 3-phosphate dehydrogenase) gene and setting the ratio of the expression level of each marker gene to the GAPDH gene in the control as 1. Calculated as

  The obtained results are shown in FIG. When β-cryptoxanthin and resveratrol were used in combination (Example 1), the gene expression levels of Runx2 type I, α1 (I) collagen, and Alkaline phosphatase, which are markers of osteoblast differentiation and bone formation, were β- Compared to cryptoxanthin alone (Comparative Example 1) and resveratrol alone (Comparative Example 2), the value was markedly higher, and it was revealed that it was effective in improving bone metabolic capacity. In particular, the effect of Example 1 far exceeds the additive effect of Comparative Example 1 and Comparative Example 2, and the combined use of β-cryptoxanthin and resveratrol synergistically increases bone metabolic capacity. Was confirmed.

Test Example 2: Effect of β-cryptoxanthin and resveratrol on fat accumulation In order to examine the anti-obesity effect of β-cryptoxanthin and resveratrol, adipocyte induction on 3T3-L1 cells exhibiting adipocyte-like properties Occasionally, β-cryptoxanthin (trade name: β-cryptoxanthin, manufactured by Shikoku Yashima Pharmaceutical Co., Ltd.) and resveratrol (trade name: Resveratrol, manufactured by Tokyo Chemical Industry Co., Ltd.) were administered to verify the action on fat accumulation. The specific test method is as follows.

  3T3-L1 cells (obtained from ATCC) are cultured in a 24-well plate in a medium (growth medium) containing DMEM / high glucose (Wako Pure Chemical Industries, Ltd.) and 10% FBS, and cultured until confluent Went. After reaching confluence, the cells were further cultured for 48 hours. Next, isobutylmethylxanthine (IBMX, manufactured by Wako Pure Chemical Industries, Ltd.) 0.5 mM, dexamethasone 1 μM, insulin 10 μg / ml (Sigma Aldrich), and various components at predetermined concentrations shown in Table 2 were added to the growth medium. Induction of 3T3-L1 cells into adipocyte-like cells was started in the differentiation induction medium prepared as described above. After 48 hours from the start of induction, the medium was replaced with a medium in which 10 μg / ml of insulin and various concentrations of various components shown in Table 2 were added to the growth medium, and thereafter the medium was similarly replaced once every two days. It was. Eight days after the start of induction, the medium is removed from the wells, and the cells are stained with Oil Red O (Primary cell), a reagent for staining fat accumulated in the cells. After washing with PBS and extraction using isopropanol, the Oil Red O staining ratio of the extract was measured. The Oil Red O staining ratio was calculated as a relative value where the staining degree of the cells in the control was 100.

  The obtained results are shown in FIG. As is clear from FIG. 2, when β-cryptoxanthin and resveratrol were used in combination (Example 2), the fat accumulation amount was β-cryptoxanthin alone (Comparative Example 3) and resveratrol alone (Comparative Example). Compared with 4), it was greatly reduced. In particular, the fat accumulation-reducing effect of Example 2 greatly exceeds the additive effect of Comparative Example 3 and Comparative Example 4, and when β-cryptoxanthin and resveratrol are used in combination, fat accumulation is caused by their synergistic action. It was confirmed that the inhibitory effect was achieved.

Test Example 3: Effect of β-cryptoxanthin and resveratrol on skin pigmentation In order to examine the effect of β-cryptoxanthin and resveratrol on skin pigment, mouse melanoma-derived B16 cells (manufactured by ATCC) were treated with β- Cryptoxanthine (trade name: β-cryptoxanthin, manufactured by Shikoku Yashima Pharmaceutical Co., Ltd.) and resveratrol (trade name: Resveratrol, manufactured by Tokyo Chemical Industry Co., Ltd.) were administered to verify the action on melanin production. The specific test method is as follows.

B16 cells were seeded in 12-well plates (Asahi Techno Glass Co., Ltd.) so as to be 3.0 × 10 ⁴ cells, and cultured in a medium containing DMEM / low glucose and 10% FBS until the next day. Subsequently, the medium was removed and replaced with a medium containing DMEM / low glucose, 10% FBS, and various concentrations of various components shown in Table 3, and the culture was further continued for 3 days. After completion of the culture, the medium was removed from the well, washed with PBS, treated with trypsin (manufactured by Wako Pure Chemical Industries), and the cells were detached and collected. The collected cells were centrifuged at 10,000 rpm for 3 minutes to prepare a pellet, which was then washed with PBS. 300 μL of 3M aqueous sodium hydroxide solution was added to the washed cells, and the cells were lysed by heating at 85 ° C. for 15 minutes, then mixed, and further heated at 85 ° C. for 10 minutes. About the melt | dissolved cell, the light absorbency in 405 nm which is an absorption spectrum of melanin was measured, and the amount of melanins was calculated | required. Moreover, 280 nm which is the absorption spectrum of protein was measured and the amount of protein was calculated | required. The ratio of the amount of melanin to the amount of protein was calculated, and a relative value with the ratio in the control as 100 was calculated.

  The obtained results are shown in FIG. From this result, when β-cryptoxanthin and resveratrol were used in combination (Example 3), the production of melanin was higher than that of β-cryptoxanthin alone (Comparative Example 3) and resveratrol alone (Comparative Example 4). And it was remarkably suppressed. The melanin production inhibitory effect of this Example 3 far surpasses the additive effect of Comparative Example 5 and Comparative Example 6, and when β-cryptoxanthin and resveratrol are used in combination, the synergistic action of these causes the melanin production inhibitory effect. Was confirmed to be played.

Test Example 4: Effects of mandarin orange extract and persimmon extract on water retention and wrinkles The following tests were conducted to examine the effects of β-cryptoxanthin and resveratrol on skin water retention and wrinkles. .

  Extraction processing was performed by immersing squeezed mandarin orange juice residue (100 g in terms of dry weight) in 500 mL of ethanol and stirring at room temperature for 24 hours. Next, the extract was collected and dried under reduced pressure to obtain a solid Unshu orange extract. The Satsuma mandarin orange extract contained 0.10% by mass of β-cryptoxanthin. Of the β-cryptoxanthins contained in the extract of mandarin orange, 20% by mass was free (β-cryptoxanthin), and 80% by mass was an ester derivative of β-cryptoxanthin.

  Separately, Kyoho's peel (100 g in terms of dry weight) was immersed in 1000 mL of water-containing ethanol (ethanol content 60% by volume) and stirred for 48 hours at room temperature. Next, the extract was collected and dried under reduced pressure to obtain a solid grape extract. The grape extract contained 0.14% by mass of resveratrol.

  Using the Wenzhou mandarin orange extract and grape extract obtained above, a cosmetic solution having the composition shown in Table 4 was prepared according to a conventional method.

20 subjects (age 45.6 years ± 15.9 years) explaining the purpose of this study were compared with a control group using a control serum and a β-cryptoxanthin group using a serum of Comparative Example 7, Dividing into 4 groups of resveratrol group using the essence of Example 8 and combination group using the essence of Example 4, a predetermined essence was applied to the forearm and face of each subject twice a day in the morning and evening. Applied. The application of each serum was continued for 28 days, and the water retention and wrinkle of the skin were evaluated before and after the test. The water retention was evaluated by measuring the transdermal moisture transpiration (TEWL: g / m ² · h) between the face part and forearm part to which the cosmetic liquid was applied using a TEWA meter (manufactured by CK). For wrinkles, the replica agent SILFLO (manufactured by Amic Group Co., Ltd.) was used to create a fine-grained replica, and the replica was irradiated with constant light from an angle of 45 °, and the number of shadows detected. The area was measured as a numerical value representing the number and depth of wrinkles, and the integrated value of the area of the detected shadow per unit area (1 cm ² wrinkle area) was calculated. In addition, water retention and wrinkle evaluation were performed after entering a room of a constant temperature and humidity environment 30 minutes before the measurement and acclimatizing in a constant environment. During the test period, subjects were prohibited from ingesting foods containing a large amount of β-cryptoxanthin, such as Unshu mandarin or papaya, foods containing resveratrol such as salmon, and supplements.

The evaluation results of skin water retention are shown in FIG. 4, and the evaluation results of wrinkles are shown in FIG. In addition, in FIG. 5, the wrinkle area ratio of 1 cm < ² > of each group calculated by setting the wrinkle area of 1 cm < ² > before the test in the control group as 100 is shown. As is clear from FIG. 4, the combination group using a serum containing β-cryptoxanthin (Unshu orange extract) and resveratrol (grape extract) after the test compared to the other groups. The decrease in skin moisture transpiration was remarkably large, and the moisture retention of the skin was greatly improved. Further, as is clear from FIG. 5, in the combined use group using the serum containing β-cryptoxanthin and resveratrol, the wrinkle improvement effect was significantly improved as compared with the other groups.

Test Example 5: Effect of β-cryptoxanthin and resveratrol on hyaluronic acid production Effect of β-cryptoxanthin and resveratrol on hyaluronic acid production on normal human epidermal keratinocytes and normal human fibroblasts Verified. The specific test method is as follows.

Normal human epidermal keratinocytes (Kurabo Co., Ltd.) and normal human fibroblasts (Kurabo Co., Ltd.) are seeded in a 24-well plate so as to be 1 × 10 ⁴ cells each, and then a medium (corner) suitable for each cell is used. of cells: Humedia-KG2, fibroblasts: FibroLife ^R Comp Kit, were cultured in manufactured by Kurabo). When the cells became subconfluent, each cell was washed with PBS, replaced with a test medium prepared by adding various components at predetermined concentrations shown in Table 5 to the medium, and cultured for 24 hours. Next, the medium was sampled, and the hyaluronic acid concentration contained in the medium was quantified with a hyaluronic acid measurement kit (manufactured by Seikagaku Corporation).

  The obtained result is shown in FIG. In both human epidermal keratinocytes and normal human fibroblasts, the amount of hyaluronic acid produced in the case of β-cryptoxanthin alone (Comparative Example 9) and resveratrol alone (Comparative Example 10) compared to the control However, when β-cryptoxanthin and resveratrol were used in combination (Example 5), the production amount of hyaluronic acid was remarkably increased by these synergistic effects. From this test result, it became clear that the combined use of β-cryptoxanthin and resveratrol is effective in increasing the amount of collagen in the epidermis and dermis.

Claims (11)

  At least one β-cryptoxanthin selected from the group consisting of β-cryptoxanthin and derivatives thereof, and at least one resveratrol selected from the group consisting of resveratrol, derivatives thereof, and salts thereof The functional composition characterized by including the kind.   The functional composition according to claim 1, wherein the β-cryptoxanthin is derived from citrus fruits.   The functional composition according to claim 1 or 2, wherein the resveratrol is derived from cocoon.   The agent according to any one of claims 1 to 3, which is used as an agent for preventing or improving bone metabolism abnormality, a fat accumulation inhibitor, a skin water retention agent, a skin pigmentation inhibitor, and / or a hyaluronic acid production promoter. Functional composition.   Any one of Claims 1-4 used as an osteoporosis prevention or improvement agent, an anti-obesity agent, a metabolic syndrome prevention or improvement agent, a moisturizer, a whitening agent, a skin beautifying agent, and / or a wrinkle prevention or improvement agent. The functional composition described in 1.   The functional composition according to any one of claims 1 to 5, which is applied by oral ingestion or transdermal administration.   Food-drinks which have a functional composition in any one of Claims 1-6.   The food additive which has a functional composition in any one of Claims 1-6.   Cosmetics which have the functional composition in any one of Claims 1-6.   The pharmaceutical which has a functional composition in any one of Claims 1-6.   Feed or pet food having the functional composition according to any one of claims 1 to 6.